1 completed, 1 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow DAT protocol 1: new trials by email Literature Review of DAT protocol 1 trials Research Report on DAT protocol 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. TAD® 600 mg/4 mL powder and solvent for solution for injection, Saline solution 0.9% of sodium chloride - Pneumonia, Myocardial Injury | Phase 3 | Unknown | Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | 178 | 2024-06-25 | 2024-11-27 |
| Clinical Performance of a Chlorhexidine Antimicrobial Dressing Chlorhexidine gluconate, Transparent Adhesive Dressing - Catheterization | Phase 2 / Phase 3 | Completed | Solventum US LLC | 68 | 2007-10-01 | 2024-10-24 |
Pneumonia (1)
Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica (1) · Solventum US LLC (1)
Italy (1)
Mark E Rupp, M.D. (1) · Noemi Evangelisti (1)